The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
March 28, 2016
View Complete Issue         Table of Contents 2019 
A Recombinant C1 Esterase Inhibitor (Ruconest) for Hereditary Angioedema (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Recombinant C1 Esterase Inhibitor (Ruconest) for Hereditary Angioedema (online only)
March 28, 2016 (Issue: 1491)
The FDA has approved Ruconest (Salix), a recombinant analog of human complement component 1 esterase inhibitor (C1INH), for treatment of acute attacks in patients with hereditary angioedema (HAE).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Recombinant C1 Esterase Inhibitor (Ruconest) for Hereditary Angioedema (online only)
Article code: 1491d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.